0000000000041729

AUTHOR

Giancarlo Logroscino

0000-0003-0423-3242

showing 18 related works from this author

Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systema…

2020

Publisher's version (útgefin grein)

Index (economics)Servicios de SaludSUSTAINABLE DEVELOPMENT GOALS030204 cardiovascular system & hematologyuniversal health coverage; sustaibale develpment goal; global burden of disease; performance;universal health coveragesystematic analysisGlobal Burden of Disease0302 clinical medicineUniversal Health InsuranceRA042111. SustainabilityPer capitaMedical economicsDisease030212 general & internal medicine10. No inequality11 Medical and Health Scienceseffective coverage of health servicesGBD 2019 Universal Health Coverage Collaboratorseducation.field_of_studyPublic healthMedical careSjúkdómar4. Education1. No povertyHealth coveragePublic Health Global Health Social Medicine and EpidemiologyGeneral MedicineHälsovetenskaper3142 Public health care science environmental and occupational healthHealth services3. Good healthGlobal burden of diseaseGlobal Burden of Disease; Health Expenditures; Humans; Universal Health Insurance; World Health OrganizationPurchasing power parityScale (social sciences)/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingLýðheilsauniversal health coveragCANCER SURVIVALACCESSperformanceHumanHeilsuhagfræðimedicine.medical_specialtyHealth coverage GBDGBDUniversal healthGBD 2019Population2019Health expenditures3122 CancersPopulation healthWorld Health Organization03 medical and health sciencesHealth systemsHeilbrigðisvísindiSDG 3 - Good Health and Well-beingGeneral & Internal MedicineDevelopment economicsHealth SciencesmedicineHeilbrigðisstefnasustaibale develpment goalAlþjóðaheilbrigðisstofnuninHumansQUALITYGlobal Burden of Disease StudyeducationPROGRESSDisease burdenPublic healthHealth services accessibilityCAREHeilbrigðisþjónusta//purl.org/pe-repo/ocde/ford#3.02.00 [https]Health ExpenditureFolkhälsovetenskap global hälsa socialmedicin och epidemiologi3121 General medicine internal medicine and other clinical medicineMorbilityAdministración de los Servicios de SaludMedical policyBusinessHealth ExpendituresHeilbrigðiskerfi
researchProduct

The burden of mental disorders, substance use disorders and self-harm among young people in Europe, 1990–2019: Findings from the Global Burden of Dis…

2022

Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAM

MedicinaRJ101Mental disordersSubstance use3121 Internal medicineEurope; Mental disorders; Mental health; Self-harm; Substance use; Young peopleCHILDRJ101 Child Health. Child health servicesSDG 3 - Good Health and Well-beingSYSTEMATIC ANALYSISInternal MedicineSelf-harmPublic Environmental & Occupational HealthRISKMCCScience & TechnologyHealth PolicyYoung people; Mental health; Mental disorders; Self-harm; Substance use; EuropeDAS3142 Public health care science environmental and occupational healthPREVALENCEEuropeMental disorderHealth Care Sciences & ServicesOncologyMental healthYoung peopleHEALTHLife Sciences & BiomedicineThe Lancet Regional Health - Europe
researchProduct

Behavioral and psychological effects of coronavirus disease-19 quarantine in patients with dementia

2020

Background: In March 2020, the World Health Organization declared a global pandemic due to the novel coronavirus SARS-CoV-2 and several governments planned a national quarantine in order to control the virus spread. Acute psychological effects of quarantine in frail elderly subjects with special needs, such as patients with dementia, have been poorly investigated. The aim of this study was to assess modifications of neuropsychiatric symptoms during quarantine in patients with dementia and their caregivers. Methods: This is a sub-study of a multicenter nation-wide survey. A structured telephone interview was delivered to family caregivers of patients with diagnosis of Alzheimer disease (AD),…

Pediatricsmedicine.medical_specialtylcsh:RC435-571IrritabilityBehavioral symptoms03 medical and health sciences0302 clinical medicinelcsh:PsychiatryPsychological symptomsmedicineDementiaApathyVascular dementiaBehavioral and psychological symptoms Behavioral symptoms Caregiver Coronavirus disease Dementia Gender Psychological symptoms QuarantineOriginal ResearchMED/26 - NEUROLOGIAPsychiatryBehavioral symptomDementia with Lewy bodiesFamily caregiversbusiness.industryBehavioral and psychological symptomsGenderBehavioral and psychological symptomCaregiver burdenmedicine.diseaseMultiinfarct dementiaCaregiver030227 psychiatryCoronavirus diseaseBehavioral and psychological symptoms; Behavioral symptoms; Caregiver; Coronavirus disease; Dementia; Gender; Psychological symptoms; QuarantinePsychiatry and Mental healthSettore MED/26 - NEUROLOGIAMED/17 - MALATTIE INFETTIVEQuarantineMED/25 - PSICHIATRIADementiaM-PSI/08 - PSICOLOGIA CLINICAPsychological symptommedicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene

2018

© 2018 Elsevier Inc.

MaleAls geneGenome-wide association studyFAMILIAL ALSALS; axonal transport; cargo; GWAS; KIF5A; WES; WGS0302 clinical medicine80 and overPsychologyGWASKIF5AAetiologycargoAged 80 and over0303 health sciencesFrench ALS ConsortiumKinesinKINESIN HEAVY-CHAINCognitive Sciencesaxonal transportHumanHereditary spastic paraplegiaNeuroscience(all)Single-nucleotide polymorphismTARGETED DISRUPTIONArticle03 medical and health sciencesGeneticsHumansAmino Acid SequenceLoss functionAgedHEXANUCLEOTIDE REPEATNeuroscience (all)MUTATIONSAmyotrophic Lateral Sclerosis3112 Neurosciences1702 Cognitive Sciencemedicine.diseaseITALSGEN ConsortiumAnswer ALS Foundation030104 developmental biologyALS Sequencing ConsortiumHuman medicine1109 Neurosciences030217 neurology & neurosurgery0301 basic medicineALS; GWAS; KIF5A; WES; WGS; axonal transport; cargo[SDV]Life Sciences [q-bio]KinesinsNeurodegenerativeGenetic analysisGenomeAMYOTROPHIC-LATERAL-SCLEROSIS3124 Neurology and psychiatryCohort StudiesPathogenesisLoss of Function MutationMissense mutation2.1 Biological and endogenous factorsAmyotrophic lateral sclerosisNYGC ALS ConsortiumGeneticsGeneral NeuroscienceALS axonal transport cargo GWAS KIF5A WES WGSMiddle AgedPhenotypeSettore MED/26 - NEUROLOGIANeurologicalProject MinE ALS Sequencing ConsortiumKinesinWESFemaleAdultBiologyGENOTYPE IMPUTATIONALS; axonal transport; cargo; GWAS; KIF5A; WES; WGS; Adult; Aged; Aged 80 and over; Amino Acid Sequence; Amyotrophic Lateral Sclerosis; Cohort Studies; Female; Genome-Wide Association Study; Humans; Kinesin; Loss of Function Mutation; Male; Middle Aged; Young AdultNOYoung AdultRare DiseasesmedicineSLAGEN ConsortiumGene030304 developmental biologyClinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) ConsortiumNeurology & NeurosurgeryHuman GenomeNeurosciencesAXONAL-TRANSPORTBrain DisordersALS; axonal transport; cargo; GWAS; KIF5A; WES; WGS;Family memberDNA-DAMAGEMOTOR-NEURONS3111 BiomedicineCohort StudieALSGenomic Translation for ALS Care (GTAC) ConsortiumWGSAmyotrophic Lateral SclerosiGenome-Wide Association StudyALS; axonal transport; cargo; GWAS; KIF5A; WES; WGS; Neuroscience (all)
researchProduct

Bovine spongiform encephalopathy and Creutzfeldt-Jakob disease: facts and uncertainties underlying the causal link between animal and human diseases

2004

Following an outbreak of bovine spongiform encephalopathy (BSE) in dairy cows in the United Kingdom (UK), 153 definite and probable human cases of new variant Creutzfeldt-Jakob disease (nvCJD) have been reported, almost exclusively in the UK. Although exposure to the BSE agent is the most plausible interpretation for the occurrence of nvCJD, the causal link between the BSE prion and nvCJD is still debated. This review discusses the pros and cons of nvCJD as a separate nosographic entity, the scientific basis for a correlation between BSE and nvCJD, the validity of the current diagnostic criteria for CJD and nvCJD, the contribution of epidemiology to the detection of a causal relation betwee…

Pediatricsmedicine.medical_specialtyMeatEncephalopathy Bovine Spongiform Encephalopathy Bovine SpongiformBovine spongiform encephalopathyEncephalopathyDermatologyDiseaseCreutzfeldt-Jakob SyndromeAnimalsHumansMedicinebovine spongiform encephalopathybusiness.industryCausal relationsGeneral MedicineNew variantmedicine.diseaseVirologyCreutzfeldt-Jakob diseaseEncephalopathy Bovine SpongiformPsychiatry and Mental healthCattleCausal linkepidemiologyNeurology (clinical)business
researchProduct

Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015 : a systematic analysi…

2016

BACKGROUND: Established in 2000, Millennium Development Goal 4 (MDG4) catalysed extraordinary political, financial, and social commitments to reduce under-5 mortality by two-thirds between 1990 and 2015. At the country level, the pace of progress in improving child survival has varied markedly, highlighting a crucial need to further examine potential drivers of accelerated or slowed decreases in child mortality. The Global Burden of Disease 2015 Study (GBD 2015) provides an analytical framework to comprehensively assess these trends for under-5 mortality, age-specific and cause-specific mortality among children under 5 years, and stillbirths by geography over time. METHODS: Drawing from ana…

PediatricsNutrition and DiseaseGlobal HealthCommunicable Disease0302 clinical medicineVoeding en ZiekteInfant MortalityCompensation law of mortalityGlobal healthMedicineLIFE EXPECTANCY030212 general & internal medicineDEVELOPING-COUNTRIES10. No inequalityMedicine(all)NEWBORN BABIESMedicine (all)Mortality rate1. No povertyDEATHPublic Health Global Health Social Medicine and EpidemiologyGeneral Medicine11 Medical And Health SciencesStillbirth3. Good healthChild MortalitySURVIVALCHILD-MORTALITYHEALTHLife Sciences & BiomedicineDEVELOPMENT GOAL 4HumanINTERVENTIONSmedicine.medical_specialtyRJINTEGRATED APPROACHDeveloping country610Communicable Diseasesneonatal03 medical and health sciencesMedicine General & Internal030225 pediatricsGeneral & Internal MedicineLife ScienceHumansGlobal Burden of Disease StudyVLAGEstimationScience & Technologybusiness.industryKlinisk medicinInfantGBD 2015 Child Mortality CollaboratorsInfant mortalityMalariaChild mortalityFolkhälsovetenskap global hälsa socialmedicin och epidemiologiLife expectancyClinical MedicineRGbusinessDemography
researchProduct

proNGF Measurement in Cerebrospinal Fluid Samples of a Large Cohort of Living Patients With Alzheimer's Disease by a New Automated Immunoassay

2021

The discovery of new biomarkers for Alzheimer's disease (AD) is essential for an accurate diagnosis, to conceive new strategies of treatments, and for monitoring the efficacy of potential disease-modifying therapies in clinical trials. proNGF levels in the cerebrospinal fluid (CSF) represent a promising diagnostic biomarker for AD, but its validation was hampered by the absence of a reliable immunoassay. In the literature, proNGF is currently measured in postmortem brain tissue by semiquantitative immunoblot. Here we describe the development and validation of a new method to measure proNGF in the CSF of living patients. This method, based on molecular size separation by capillary electropho…

OncologyAgingmedicine.medical_specialtydiagnosisCognitive NeuroscienceNeurosciences. Biological psychiatry. NeuropsychiatryDiseaseSettore BIO/09 - FisiologiaCerebrospinal fluidneurodegenerative diseaseInternal medicinemedicineDiagnostic biomarkerneurodegenerative diseasesproNGFimmunoassayOriginal Researchmedicine.diagnostic_testbusiness.industrySignificant differenceAlzheimer's diseaseLarge cohortdiagnosiImmunoassayBiomarker (medicine)biomarkerAutomated immunoassaybusinessRC321-571Neuroscience
researchProduct

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countr…

2015

Summary Background The Global Burden of Disease Study 2013 (GBD 2013) aims to bring together all available epidemiological data using a coherent measurement framework, standardised estimation methods, and transparent data sources to enable comparisons of health loss over time and across causes, age–sex groups, and countries. The GBD can be used to generate summary measures such as disability-adjusted life-years (DALYs) and healthy life expectancy (HALE) that make possible comparative assessments of broad epidemiological patterns across countries and time. These summary measures can also be used to quantify the component of variation in epidemiology that is related to sociodemographic develo…

GerontologyMaleCHANGING RELATIONNutrition and DiseaseMESH : Life ExpectancyMESH : AgedECONOMIC-DEVELOPMENTPoison controlMESH: Global HealthGlobal HealthSocioeconomic FactorCommunicable DiseaseMESH : Chronic DiseaseHealth TransitionVoeding en ZiekteQuality-Adjusted Life YearSELF-RATED HEALTHMESH : Socioeconomic FactorsMedicineMESH : FemaleMESH: Mortality Premature2. Zero hungerMESH: Agededucation.field_of_studyMESH: Middle AgedMortality rateMedicine (all)GBD2013 diseases[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieGeneral MedicineMiddle Aged3. Good healthMESH : Wounds and InjuriesEpidemiological transitionMESH: Quality-Adjusted Life YearsMESH: Communicable DiseasesNONCOMMUNICABLE DISEASESFemaleQuality-Adjusted Life YearsMESH: Life ExpectancyMESH: Health TransitionHumanMESH: Socioeconomic FactorsACUTE MYOCARDIAL-INFARCTIONMESH : MaleMORTALITY TRENDSPopulationMESH : Health TransitionCommunicable DiseasesArticleLife ExpectancyEUROPEAN-UNIONSDG 3 - Good Health and Well-beingGeneral & Internal MedicineSYSTEMATIC ANALYSISDisability-adjusted life yearHumansLife ScienceMESH : Middle AgedMortalityeducationPrematureMESH : Mortality PrematureVLAGAgedMESH: Humansbusiness.industryMortality PrematureMESH: Chronic DiseaseMESH : Communicable DiseasesWounds and InjurieMESH : HumansMESH : Quality-Adjusted Life YearsNon-communicable diseaseAged; Chronic Disease; Communicable Diseases; Female; Global Health; Humans; Male; Middle Aged; Mortality Premature; Quality-Adjusted Life Years; Socioeconomic Factors; Wounds and Injuries; Health Transition; Life Expectancy; Medicine (all)medicine.diseaseMESH: MaleLOW SOCIOECONOMIC-STATUSYears of potential life lostSocioeconomic Factors[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMESH: Wounds and InjuriesChronic DiseaseLife expectancyRISK-FACTORSMESH : Global HealthWounds and Injuries[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessMESH: FemaleDemographyLancet
researchProduct

HFE p.H63D polymorphism does not influence ALS phenotype and survival.

2015

It has been recently reported that the p.His63Asp polymorphism of the HFE gene accelerates disease progression both in the SOD1 transgenic mouse and in amyotrophic lateral sclerosis (ALS) patients. We have evaluated the effect of HFE p.His63Asp polymorphism on the phenotype in 1351 Italian ALS patients (232 of Sardinian ancestry). Patients were genotyped for the HFE p.His63Asp polymorphism (CC, GC, and GG). All patients were also assessed for C9ORF72, TARDBP, SOD1, and FUS mutations. Of the 1351 ALS patients, 363 (29.2%) were heterozygous (GC) for the p.His63Asp polymorphism and 30 (2.2%) were homozygous for the minor allele (GG). Patients with CC, GC, and GG polymorphisms did not significa…

MaleAgingSurvivalSettore MED/03 - GENETICA MEDICAMiceSuperoxide Dismutase-1C9orf72HFE polymorphismAmyotrophic lateral sclerosisAmyotrophic lateral sclerosis; HFE polymorphisms; Phenotype; SOD1; Survival; Aged; Alleles; Amyotrophic Lateral Sclerosis; Animals; Disease Progression; Female; Hemochromatosis Protein; Histocompatibility Antigens Class I; Humans; Italy; Male; Membrane Proteins; Mice; Middle Aged; Polymorphism Genetic; Superoxide Dismutase; Superoxide Dismutase-1; Survival Rate; Genetic Association Studies; PhenotypeHFE polymorphismsMembrane ProteinAlleleAmyotrophic lateral sclerosis; HFE polymorphisms; Phenotype; SOD1; Survival; Neurology (clinical); Neuroscience (all); Aging; Developmental Biology; Geriatrics and GerontologyGeneral NeuroscienceSOD1Middle AgedPhenotypeSurvival RatePhenotypeItalyAmyotrophic lateral sclerosis; HFE polymorphisms; SOD1; phenotype; survivalDisease ProgressionFemaleHumanmedicine.medical_specialtySOD1Amyotrophic lateral sclerosis; HFE polymorphisms; Phenotype; SOD1; Survival;Genetic Association StudieBiologyTARDBPArticleGeneticInternal medicinemedicineAnimalsHumansAllelePolymorphismHemochromatosis ProteinSurvival rateAmyotrophic lateral sclerosiAllelesGenetic Association StudiesAgedNeuroscience (all)Polymorphism GeneticAnimalSuperoxide DismutaseAmyotrophic Lateral SclerosisHistocompatibility Antigens Class Inutritional and metabolic diseasesMembrane Proteinsmedicine.diseaseMinor allele frequencyEndocrinologyImmunologyNeurology (clinical)Geriatrics and GerontologyDevelopmental BiologyNeurobiology of aging
researchProduct

C9ORF72 in a Large Series of Italian and Sardinian Familial and Sporadic ALS Patients (IN9-1.003)

2012

Objective: To assess the frequency and the phenotype of a large series of Italian sALS and fALS with C9ORF72 repeat expansions. Background Recently we found that large expansions of hexanucleotide repeats (GGGGCC) in the first intron of the C9ORF72 gene, located in the chromosome 9p21, are related to familial and sporadic ALS cases(Renton et al, 2011). Design/Methods: We assessed 126 index fALS (106 Italians, 20 of Sardinians) and 601 sALS (485 Italians, 116 Sardinians), negative for other ALS-related genes mutations. Patients were collected through the ITALSGEN consortium. Repeat primer PCR to screen the presence of the hexanucleotide expansion in the first intron of C9ORF72 have been perf…

business.industryLarge seriesPedigree chartmedicine.diseasePenetranceC9orf72NothingAnticipation (genetics)MedicineNeurology (clinical)businessTrinucleotide repeat expansionDemographyFrontotemporal dementiaNeurology
researchProduct

The Impact of COVID-19 Quarantine on Patients With Dementia and Family Caregivers: A Nation-Wide Survey

2021

IntroductionPrevious studies showed that quarantine for pandemic diseases is associated with several psychological and medical effects. The consequences of quarantine for COVID-19 pandemic in patients with dementia are unknown. We investigated the clinical changes in patients with Alzheimer’s disease and other dementias, and evaluated caregivers’ distress during COVID-19 quarantine.MethodsThe study involved 87 Italian Dementia Centers. Patients with Alzheimer’s Disease (AD), Dementia with Lewy Bodies (DLB), Frontotemporal Dementia (FTD), and Vascular Dementia (VD) were eligible for the study. Family caregivers of patients with dementia were interviewed by phone in April 2020, 45 days after …

AgingPediatricsmedicine.medical_specialtyCognitive Neurosciencelcsh:RC321-57103 medical and health sciences0302 clinical medicinemental disordersAlzheimer’s disease BPSD caregiver burden COVID-19 dementia quarantinemedicineDementiaBPSD030212 general & internal medicineVascular dementialcsh:Neurosciences. Biological psychiatry. NeuropsychiatryAlzheimer’s disease; BPSD; caregiver burden; COVID-19; dementia; quarantineDepression (differential diagnoses)Original ResearchM-PSI/05 - PSICOLOGIA SOCIALEMED/26 - NEUROLOGIAcaregiver burdenDementia with Lewy bodiesFamily caregiversbusiness.industryquarantineCOVID-19Odds ratiomedicine.diseaseSettore MED/26 - NEUROLOGIADistressMED/17 - MALATTIE INFETTIVEbusinessAlzheimer’s disease030217 neurology & neurosurgeryNeuroscienceFrontotemporal dementiadementia
researchProduct

Three Decades of Comprehensive Geriatric Assessment: Evidence Coming From Different Healthcare Settings and Specific Clinical Conditions

2017

Comprehensive geriatric assessment (CGA) is a multidisciplinary diagnostic and treatment process that identifies medical, psychosocial, and functional capabilities of older adults to develop a coordinated plan to maximize overall health with aging. Specific criteria used by CGA programs to evaluate patients include age, medical comorbidities, psychosocial problems, previous or predicted high healthcare utilization, change in living situation, and specific geriatric conditions. However, no universal criteria have been agreed upon to readily identify patients who are likely to benefit from CGA. Evidence from randomized controlled trials and large systematic reviews and meta-analyses suggested…

Maleendocrine systemmedicine.medical_specialtyHistory 21st Centurylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialMultidisciplinary approachlawemergency medicineHealth careHumansMedicinecancerCognitive DysfunctionMusculoskeletal Diseases030212 general & internal medicineIntensive care medicineGeriatric AssessmentGeneral NursingHealth policyNursing (all)2901 Nursing (miscellaneous)Agedcognitive impairmentAged 80 and overGeriatricsgeriatricsFrailtybusiness.industrycancer; cognitive impairment; emergency medicine; Frailty; geriatrics; orthopedics; Nursing (all)2901 Nursing (miscellaneous); Medicine (all); Health PolicyMedicine (all)Health PolicyGeriatric assessmentGeneral MedicineHistory 20th CenturySystematic reviewFrailty cancer cognitive impairment emergency medicine geriatrics orthopedicsPhysical therapyorthopedicsFemaleHealth FacilitiesGeriatrics and GerontologybusinessPsychosocial030217 neurology & neurosurgery
researchProduct

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for …

2015

Background Up-to-date evidence on levels and trends for age-sex-specific all-cause and cause-specific mortality is essential for the formation of global, regional, and national health policies. In the Global Burden of Disease Study 2013 (GBD 2013) we estimated yearly deaths for 188 countries between 1990, and 2013. We used the results to assess whether there is epidemiological convergence across countries. Methods We estimated age-sex-specific all-cause mortality using the GBD 2010 methods with some refinements to improve accuracy applied to an updated database of vital registration, survey, and census data. We generally estimated cause of death as in the GBD 2010. Key improvements included…

MaleAgingPediatricsNutrition and DiseaseDatabases FactualDisease030204 cardiovascular system & hematologyGlobal HealthMedical and Health SciencesDOUBLE-BLIND0302 clinical medicineAdolescent; Adult; Aged; Aged 80 and over; Cause of Death; Child; Child Mortality; Child Preschool; Databases Factual; Female; Global Health; Humans; Infant; Infant Newborn; Life Expectancy; Life Tables; Male; Middle Aged; Models Statistical; Mortality; Sex Distribution; Young AdultModelsVoeding en ZiekteCause of DeathEpidemiologyGlobal health80 and over2.2 Factors relating to the physical environmentLife Tables030212 general & internal medicineAetiologyChildINFLUENZAE TYPE-B11 Medical and Health SciencesCause of deathPediatricAged 80 and overPLACEBO-CONTROLLED-TRIALLife TableMortality rateMedicine (all)1. No povertyGeneral MedicineCHILDHOOD PNEUMONIAMiddle AgedStatistical3. Good healthInfectious DiseasesChild PreschoolPNEUMOCOCCAL CONJUGATE VACCINEChild MortalityFemaleInfectionLife Sciences & BiomedicineHumanAdultmedicine.medical_specialtyAdolescentINTEGRATED APPROACHCHILDREN YOUNGER187 COUNTRIESDatabase03 medical and health sciencesDatabasesYoung AdultMedicine General & InternalLife ExpectancyGeneral & Internal MedicinemedicineLife ScienceHumansMortalitySex DistributionPreschoolFactualVLAGAgedScience & TechnologyModels Statisticalbusiness.industryPreventionPOPULATION HEALTHInfant NewbornENTERIC MULTICENTERInfantGBD 2013 Mortality and Causes of Death CollaboratorsNewbornVerbal autopsyChild mortalityGood Health and Well BeingLife expectancyRISK-FACTORSbusiness2.4 Surveillance and distributionDemographyModel
researchProduct

The parkin gene is not a major susceptibility locus for typical late-onset Parkinson's disease

2001

We investigated the parkin gene in 118 patients with typical Parkinson's disease (PD), i. e. in patients who had an onset of PD after the age of 45 years. The study group included 95 subjects with sporadic PD and 23 subjects from 18 families with autosomal recessive PD. No pathogenetic mutations in the parkin gene were detected either in familial or in sporadic patients. Our findings indicate that the parkin gene is not involved in the pathogenesis of classic late-onset PD.

Malemedicine.medical_specialtyNeurologyParkinson's diseaseUbiquitin-Protein LigasesDNA Mutational AnalysisMolecular Sequence DataLate onsetGenes RecessiveDermatologyDiseaseParkinPathogenesisLigasesParkinsonian DisordersmedicineHumansPoint MutationGenetic Predisposition to DiseaseGenetic TestingAge of OnsetAgedGeneticsbusiness.industryGeneral MedicineExonsParkin geneMiddle Agedmedicine.diseasenervous system diseasesPsychiatry and Mental healthSusceptibility locusChromosomes Human Pair 6FemaleNeurology (clinical)business
researchProduct

FUS MUTATIONS IN SPORADIC AMYOTROPHIC LATERAL SCLEROSIS: CLINICAL AND GENETIC ANALYSIS

2012

Fused in sarcoma (FUS) or translocation in liposarcoma (TLS), a DNA/RNA-binding protein, causes a dominant autosomal inherited form of amyotrophic lateral sclerosis (ALS), ALS 6. Its main role in neurodegeneration is highlighted by the presence of cytoplasmic accumulation of its mutant protein form in ALS patients. To further define the frequency and spectrum of FUS gene mutations, we have performed a molecular screening of a cohort of 327 Italian patients from Southern Italy with sporadic ALS (SALS). We identified 4 patients carrying 3 different missense mutations and several polymorphisms. Two different substitutions occurring in the same amino acidic position have been observed in 2 pati…

MaleAgingPopulationDNA Mutational AnalysisBiologyGene mutationmedicine.disease_causeGenetic analysisFUS geneMutant proteinALS; FUS gene; mutation; sporadicmedicineMissense mutationHumansGenetic Predisposition to DiseaseAmyotrophic lateral sclerosiseducationAgedGeneticsAged 80 and overNeurologic ExaminationMutationeducation.field_of_studyGeneral NeuroscienceNeurodegenerationAmyotrophic Lateral SclerosisExonsMiddle AgedALS; FUS gene; Mutation; Sporadicmedicine.diseaseMagnetic Resonance ImagingSettore BIO/18 - GeneticasporadicMutationRNA-Binding Protein FUSFemaleSettore MED/26 - NeurologiaNeurology (clinical)ALSGeriatrics and GerontologyDevelopmental Biology
researchProduct

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risk…

2015

Summary Background The Global Burden of Disease, Injuries, and Risk Factor study 2013 (GBD 2013) is the first of a series of annual updates of the GBD. Risk factor quantification, particularly of modifiable risk factors, can help to identify emerging threats to population health and opportunities for prevention. The GBD 2013 provides a timely opportunity to update the comparative risk assessment with new data for exposure, relative risks, and evidence on the appropriate counterfactual risk distribution. Methods Attributable deaths, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs) have been estimated for 79 risks or clusters of risks using the GBD 2…

MaleFine particulate matterNutrition and DiseaseMESH : SanitationHealth BehaviorDiseasesMESH: Metabolic DiseasesMESH: Global Health030204 cardiovascular system & hematologyMESH: Risk AssessmentGlobal HealthMESH : Nutritional StatusMESH: Occupational Exposure0302 clinical medicineUnsafe SexMESH: Risk FactorsRisk FactorsVoeding en ZiekteMedicineAir-pollutionMESH : Female030212 general & internal medicineMESH : Risk AssessmentSanitationWasting2. Zero hungerFactors de risc en les malaltiesMedicine (all)[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologiePublic Health Global Health Social Medicine and EpidemiologyGeneral MedicineMESH : Occupational DiseasesMESH: Nutritional StatusAll-cause mortalityMESH : Risk FactorshumanitiesEnvironmental Exposure; Female; Global Health; Health Behavior; Humans; Male; Metabolic Diseases; Nutritional Status; Occupational Diseases; Occupational Exposure; Risk Assessment; Risk Factors; Sanitation; Medicine (all)Tobacco smoking3. Good healthOccupational DiseasesNutritional StatuMESH : Occupational ExposureMESH : Metabolic DiseasesCohortFemalemedicine.symptomRisk assessmentBlood-pressureHumanMESH: Occupational DiseasesRisk factors in diseasesCoronary-heart-diseaseMESH : MaleMESH: Health BehaviorMESH: Environmental ExposureNutritional StatusPopulation healthBody-mass indexRisk Assessment03 medical and health sciencesHousehold cookingMetabolic DiseasesCardiovascular-diseaseEnvironmental healthGeneral & Internal MedicineOccupational Exposureparasitic diseasesLife ScienceMESH: SanitationHumansRisk factorMESH : Health BehaviorVLAGGBD2013MESH: Humansbusiness.industryRisk FactorGlobal Burden of Disease Study; 79 behavioural environmental and occupational and metabolic risksLong-term exposureMESH : HumansCAUSE-SPECIFIC MORTALITYEnvironmental ExposureMESH: MaleMetabolic DiseaseOccupational DiseaseFolkhälsovetenskap global hälsa socialmedicin och epidemiologiMALE BRITISH DOCTORSYears of potential life lostRelative riskMalaltiesMESH : Global HealthOUTDOOR AIR-POLLUTION[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessMESH : Environmental ExposureMESH: FemaleLancet
researchProduct

Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis.

2012

ABSTRACT Objective: Recent evidence suggests that intermediate-length polyglutamine (PolyQ) expansions in the ataxin-2 ( ATXN-2 ) gene are a risk factor for amyotrophic lateral sclerosis (ALS). This work was undertaken with the aim to investigate the frequency of ataxin-1 ( ATXN-1 ) and ATXN-2 PolyQ expansions in a cohort of patients with sporadic ALS (sALS) and patients with familial ALS (fALS) from southern Italy. Methods: We assessed the PolyQ lengths of ATXN-1 and ATXN-2 in 405 patients with sALS, 13 patients with fALS, and 296 unrelated controls without history of neurodegenerative disorders. Results: We found significantly higher intermediate PolyQ expansions ≥32 for ATXN-1 alleles an…

OncologyAdultMalemedicine.medical_specialtyGenotypeALS; ATXN-1; ATXN-2Ataxin 1Nerve Tissue ProteinsRisk FactorsInternal medicinemedicineHumansIn patientGenetic Predisposition to DiseaseAmyotrophic lateral sclerosisAlleleRisk factorAge of OnsetATXN-2ATXN-1AllelesAtaxin-1AgedAged 80 and overbiologybusiness.industryAmyotrophic Lateral SclerosisAge FactorsNuclear ProteinsMiddle Agedmedicine.diseaseIncreased riskPOLYGLUTAMINE EXPANSIONS; HEXANUCLEOTIDE REPEAT; ALS; TYPE-1; NEURODEGENERATION; PHENOTYPE; GENETICS; PROTEIN; C9ORF72; RISKAtaxinsItalyAtaxinCohortbiology.proteinFemaleSettore MED/26 - NeurologiaNeurology (clinical)ALSbusinessPeptidesTrinucleotide Repeat Expansion
researchProduct

Apolipoprotein E genotype does not influence the progression of multiple sclerosis

2003

OBJECTIVE: To investigate the association between apolipoprotein E (APOE) polymorphisms and the progression of MS. METHODS: We investigated 428 subjects affected by clinically defined MS, with a disease duration of at least three years. We collected data concerning the age at onset of MS, clinical type, disease duration and disability according to the expanded disability status scale (EDSS). We also calculated the progression index (PI) to evaluate disease progression. APOE genotyping and the -491 A/T polymorphism of the APOE promoter were determined. RESULTS: No association was observed between the APOE epsilon4 allele and clinical characteristics of our study population. We also investiga…

OncologyApolipoprotein EAdultMalemedicine.medical_specialtyMultiple SclerosisGenotypeAdolescentOdds Ratio; Polymorphism Genetic; Chi-Square Distribution; Humans; Disease Progression; Apolipoproteins E; Genotype; Multiple Sclerosis; Adult; Confidence Intervals; Adolescent; Statistics Nonparametric; Female; MalePopulationAPOE polymorphismBiologyStatistics NonparametricApolipoproteins EGeneticPolymorphism (computer science)Internal medicineGenotypeMultiple SclerosimedicineOdds RatioConfidence IntervalsHumansNonparametricPolymorphismeducationGenotypingAPOE promotereducation.field_of_studyExpanded Disability Status ScalePolymorphism GeneticChi-Square DistributionMS progressionStatisticsOdds ratioNeurologyImmunologyDisease ProgressionPopulation studylipids (amino acids peptides and proteins)FemaleSettore MED/26 - NeurologiaNeurology (clinical)Confidence IntervalHuman
researchProduct